Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Susan F SlovinKaren KnudsenSusan HalabiRenee de LeeuwAyesha A ShafiPraneet KangSteven WolfBin LuoAnuradha GopalanTracy CurleyMark FlemingAna MolinaCelina FernandezWilliam Kevin KellyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
AAP + C was safe with improved rPFS, OS duration, and a higher proportion of PSA declines. This suggests that AAP + C given earlier rather than sequentially may benefit some men. Further work is needed to identify this population.